PainChek Ltd traded at 0.03 this Thursday July 7th, increasing 0.001 or 3.13 percent since the previous trading session. Looking back, over the last four weeks, PainChek Ltd gained 2.94 percent. Over the last 12 months, its price fell by 46.77 percent. Looking ahead, we forecast PainChek Ltd to be priced at 0.03 by the end of this quarter and at 0.03 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Alcidion Group Ltd 0.13 -0.01 -3.85% -65.75%
Fisher & Paykel Healthcare 19.27 0.14 0.73% -31.67%
Pro Medicus Ltd 45.19 -0.03 -0.07% -21.11%
Resapp Health Ltd 0.13 0 0% 195.45%
ResMed 32.14 -0.36 -1.11% -4.09%
Volpara Health Technologies Ltd 0.54 0.01 0.93% -53.85%

PainChek Ltd
PainChek Limited is an Australia-based company, that develops pain assessment technologies. The Company’s principal activities are development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. Its Paincheck is an Adult and Infant pain assessment applications. Its PainChek technology uses cameras in smartphones and tablets to capture a brief video of the person, which is analyzed in real time using facial recognition software to detect the presence of facial micro-expressions that are indicative of the presence of pain. Its Paincheck uses artificial intelligence (AI) to automatically assess the micro-facial features of pain. Its PainChek technology has multiple regulatory clearances, including TGA (Australia) and CE Mark (Europe) for use as a class 1 medical device to assess pain in people who are unable to reliably verbalize, such people with dementia.